Yep, several testing groups have submitted several degradation tests to Janoshik over the last year or so. There was even a testing group that measured tirzepatide degradation under sous vide conditions . There was some loss in purity/potency , but not as much as one would think. This is a sturdy peptide, significant loss of potency after 3 months is highly unlikely after reconstitution.
2 Likes
Unopened is key. Once reconstituted and used it begins degrading. I can confirm this from personal experience.
That, or total mg in these vials varies slightly.
1 Like
The Eli Lilly product is reconstituted, while it degrades faster than lyophilized, it is still very slow. Most people are finding Tirz to be very effective 3-5 months after reconstitution (but many don’t like to extend beyond 6 weeks or so for bacterial reasons in opened vials).
3 Likes
My issue might have been variation in strength between vials.
That may be. I really like having double batch tested Chinese peptides, vs purchasing single vial peptides from US based research vendors. You never know if the vials are from different lots and if the provided CoA matches the lot.
2 Likes
A new one coming?
CT-859 is a biased dual GLP-1R/GIPR agonist and does not induce receptor internalization
Biased agonism of GLP-1R and GIPR enhances glucose lowering and weight loss, with dual GLP-1R/GIPR biased agonism yielding greater efficacy
https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(25)00229-0
2 Likes
I’m noticing better breathing while laying down and my CPAP score when waking up the past week has been below 1 AHI. I’ve only just gone up to 5mg of Tirzepatide as well. Really happy with my results so far.
Do you still use CPAP?
1 Like
Very cool paper, thanks for sharing. This is great for future development of multi agonists, and shows there are still efficiencies to be extracted from dual and tri agonists.
This paper talks about the cAmp (biased ) vs the b-arrestin pathway, in the context of design a dual GLP1 and GIP agonist, which could work better than tirzepatide.
This is very cool to see because it shows that the tirzepatide design is not "optimal ", and that the way to get better incretin weight loss drugs is not necessarily by adding receptors they agonize, ie tri or quad receptor agonists.
1 Like